Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

Videos | EP Device Monitoring Systems

VIDEO: Rising Interest in Remote Monitoring of EP Devices in the COVID-19 Era

Robert Kowal, M.D., chief medical officer of the Medtronic cardiac rhythm and heart failure division, said there has ...

December 22, 2020

HeartMate 3 heart pump is now approved for use for pediatric patients battling advanced heart failure offering a new treatment option for this underserved population

News | Heart Failure

FDA Approves Abbott's HeartMate 3 VAD for Pediatric Patients

December 21, 2020 — U.S. Food and Drug Administration (FDA) approved updated labeling December 17 for Abbott's HeartMate ...

December 21, 2020

The Digisonics' cardiovascular information system (CVIS) system.

News | Cardiovascular Information Systems (CVIS)

Intelerad Acquires Digisonics to Expand its Enterprise Imaging Workflow

December 16, 2020 - Intelerad Medical Systems, a provider of enterprise imaging workflow solutions, has acquired ...

December 16, 2020

Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) so the company to initiate a U.S. clinical study of its Tria biopolymer mitral surgical heart valve.

News | Heart Valve Technology

Foldax to Initiate FDA Clinical Study of Biopolymer Mitral Heart Valve

December 14, 2020 - Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an ...

December 14, 2020

SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to treat a variety of hypertensive disorders, announced that it has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The TIVUS System for renal artery denervation treats resistant hypertension, which is defined as blood pressure that remains above 140/90 mmHg despite use of three antihypertensive medications of different classes at the best tolerated doses.

News | Renal Denervation

FDA Grants Breakthrough Device Designation for the TIVUS Renal Artery Denervation System

December 9, 2020 — SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to ...

December 09, 2020

Feature

The DAIC November-December 2020 Digital Edition

View the November-December 2020 digital edition of Diagnostic and Interventional Cardiology (DAIC) magazine, include ...

December 03, 2020

cyanosis, cyantosis COVID-positive infant.

News | Coronavirus (COVID-19)

COVID-19 Can Impact Hearts in Young Children

December 2, 2020 — A 2-month-old infant diagnosed with COVID-19 (SARS-CoV-2) experienced reversible myocardial injury ...

December 02, 2020

CMS coverage changes effective as of Dec. 2, 2020 will open up the use of LVADs to more Medicare patients, including use of the HeartWare and HeartMate ventricular assist devices.

News | Heart Failure

CMS Updates Coverage Policies for Artificial Hearts and Ventricular Assist Devices

December 2, 2020 — The Centers for Medicare and Medicaid Services (CMS) finalized updates to Medicare coverage policies ...

December 02, 2020

COVID-19 cardiology related content continues to be among the top performers on the DAIC website in November 2020. TAVR also topped headlines with Boston Scientific taking its Lotus valve off the market and a review of TAVR registry data showing it is now the dominant method of aortic valve replacement in the United States. #DAIC

Feature | Cardiovascular Business | Dave Fornell, Editor

December 1, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

December 01, 2020

A recent publication demonstrated procedural efficiency for MitraClip transcatheter mitral valve repair (TMVR) with use of the Baylis VersaCross RF Transseptal Solution, reporting guide delivery from femoral access in under 7.5 minutes.

News | Hemodynamic Monitoring Systems

Study Finds TMVR Procedural Efficiency Using the VersaCross RF Transseptal Solution

December 1, 2020 — A recent publication demonstrated procedural efficiency for MitraClip transcatheter mitral valve ...

December 01, 2020

Results from study of more than 14,000 patients across the United States show the heavy impact of cardiac disease on hospitalized COVID patients. COVID-19 patients with cardiovascular diseases have in-hospital mortality rates of between 25 to 38 percent. #AHA #AHA20 #AHA2020 #COVID19 #Coronavirus #SARSCoV2

News | Coronavirus (COVID-19) | Dave Fornell, Editor

COVID-19 Patients With Cardiovascular Disease Have In-hospital Mortality Rates of 25 to 38 Percent

November 18, 2020 — A late-breaking study at the 2020 American Heart Association (AHA) Scientific Sessions showed nearly ...

November 18, 2020

RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm

News

Rivaroxaban is Comparable to Warfarin for Bioprosthetic Mitral Valves and AF

November 18, 2020 — The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial ...

November 18, 2020

Black patient being tested for COVID-19 using a nasal swab PCR test. black adults with COVID-19 were far more likely to be hospitalized than their white counterparts according to data from the AHA COVID-19 Cardiovascular Disease Registry. #AHA #AHA20 #AHA2020 #COVID19 #SARSCoV2

Feature | Coronavirus (COVID-19)

COVID-19 Cardiovascular Registry Details Disparities Among Hospitalized Patients

November 18, 2020 -- A new American Heart Association (AHA) collaborative model for COVID-19 (SARS-CoV-2) research ...

November 18, 2020

Feature | Heart Valve Technology

TAVR Is Now Dominant Form of Aortic Valve Replacement in the United States

November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more ...

November 17, 2020

oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system.

Feature | Heart Valve Technology | Dave Fornell, Editor

Boston Scientific Pulls Lotus Edge TAVR Valve Off The Market

November 17, 2020 — Boston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge ...

November 17, 2020